AT-130 is an antiviral agent.1,2 It is a non-nucleoside inhibitor of hepatitis B virus (HBV) replication in wild-type and rtL180M, rtM204I, and rtL180M + rtL204V lamivudine-resistant strains of HBV (IC50s = 2.4, 1.6, 5.1, and 1.3 ?M, respectively).2 AT-130 inhibits viral DNA synthesis in HBV-infected HepAD38 cells (EC50 = 0.13 ?M) and reduces the amount of encapsidated RNA in HBV-infected HepG2 cells.2,3
1.Perni, R.B., Conway, S.C., Ladner, S.K., et al.Phenylpropenamide derivatives as inhibitors of hepatitis B virus replicationBioorg. Med. Chem. Lett.10(23)2687-2690(2000) 2.Delaney, W.E., IV, Edwards, R., Colledge, D., et al.Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitroAntimicrob. Agents Chemother.46(9)3057-3060(2002) 3.Feld, J.J., Colledge, D., Sozzi, V., et al.The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packagingAntiviral Res.76(2)168-177(2007)